Peptide therapies are gaining momentum across precision healthcare, longevity, medical aesthetics, and other areas of medicine—but the regulatory landscape surrounding them remains complex.
In this episode of Skytale Insights, Ben Hernandez sits down with Michael Byrd and Brad Adatto, co-founders of ByrdAdatto, to unpack the evolving landscape of peptide regulation and what it means for healthcare practice owners, providers, and investors.
The conversation explores the FDA Pharmacy Compounding Advisory Committee’s recommendation involving six peptides and, importantly, why that recommendation does not mean those peptides have received FDA approval. Michael and Brad break down the distinction between federal compounding rules and state-level regulation of the practice of medicine, including how standards of care, sourcing, patient consent, advertising, and malpractice coverage can affect a practice’s ability to offer peptide therapies.
The group also examines the business implications of peptide regulation as demand grows across precision healthcare. From private equity interest and M&A considerations to the risks of adding a new service line too quickly, they discuss how practices can balance innovation and patient demand with compliance, risk management, and long-term enterprise value.
In this episode, you’ll learn:
- What the FDA’s recent peptide recommendation actually means—and what it does not mean for healthcare providers
- How federal peptide regulation intersects with state medical board requirements and standards of care
- The difference between 503A and 503B compounding pharmacies and why peptide sourcing matters
- What practices should evaluate before adding peptide therapy as a new service line, including science, compliance, insurance, patient consent, and advertising
- How private equity groups and strategic buyers are beginning to evaluate peptides and precision healthcare opportunities
- Why a thoughtful compliance and risk-management strategy can help practices pursue innovation while protecting patients, providers, and long-term business value